NMR-based Model Reveals the Structural Determinants of Mammalian Arylamine N-Acetyltransferase Substrate Specificity

Journal of Molecular Biology

Volumn 363, Issue 1, 2006, Pages 188-200

  Zhang, Naixia ^a   Liu, Li ^a   Liu, Fen ^a   Wagner, Carston R ^a   Hanna, Patrick E ^a   Walters, Kylie J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

arylamine carcinogens; arylamine N acetyltransferase; NMR; structural determinants; substrate specificity

Indexed keywords

4 AMINOBENZOIC ACID; 4 BIPHENYLAMINE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; TOLUIDINE DERIVATIVE;

ACETYLATION; ARTICLE; BINDING AFFINITY; BLADDER CANCER; CATALYSIS; DETOXIFICATION; ENZYME SPECIFICITY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; TOBACCO;

MAMMALIA; NICOTIANA TABACUM;

EID: 33748764946     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.08.026     Document Type: Article

References (54)

1. Riddle B., and Jencks W.P. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J. Biol. Chem. 246 (1971) 3250-3258
2. Weber W.W., and Hein D.W. N-Acetylation pharmacogenetics. Pharmacol. Rev. 37 (1985) 25-79
3. Evans D.A. N-Acetyltransferase. Pharmacol. Ther. 42 (1989) 157-234
4. Hughes H.B. On the metabolic fate of isoniazid. J. Pharmacol. Expt. Ther. 109 (1953) 444-452
5. Hein D.W., Rustan T.D., Doll M.A., Bucher K.D., Ferguson R.J., Feng Y., et al. Acetyltransferases and susceptibility to chemicals. Toxicol Letters 64-65 (1992) 123-130
6. Vineis P., Bartsch H., Caporaso N., Harrington A.M., Kadlubar F.F., Landi M.T., et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369 (1994) 154-156
7. Markowitz S.B., and Levin K. Continued epidemic of bladder cancer in workers exposed to ortho-toluidine in a chemical factory. J. Occup. Environ. Med. 46 (2004) 154-160
8. Lower Jr. G.M., Nilsson T., Nelson C.E., Wolf H., Gamsky T.E., and Bryan G.T. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29 (1979) 71-79
9. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 29-42
10. Garcia-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D.W., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
11. Hein D.W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507 (2002) 65-77
12. Butcher N.J., Arulpragasam A., and Minchin R.F. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J. Biol. Chem. 279 (2004) 22131-22137
13. Liu F., Zhang N., Zhou X., Hanna P.E., Wagner C.R., Koepp D.M., and Walters D.M. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. 361 (2006) 482-492
14. Gan J., Skipper P.L., Gago-Dominguez M., Arakawa K., Ross R.K., Yu M.C., and Tannenbaum S.R. Alkylaniline-hemoglobin adducts and risk of non-smoking-related bladder cancer. J. Natl Cancer Inst. 96 (2004) 1425-1431
15. Dupret J.M., and Grant D.M. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J. Biol. Chem. 267 (1992) 7381-7385
16. Weber W.W., and Cohen S.N. N-Acetylation of drugs: isolation and properties of an N-acetyltransferase from rabbit liver. Mol. Pharmacol. 3 (1967) 266-273
17. Steinberg M.S., Cohen S.N., and Weber W.W. Isotope exchange studies on rabbit liver N-acetyltransferase. Biochim. Biophys. Acta 235 (1971) 89-98
18. Sinclair J.C., Sandy J., Delgoda R., Sim E., and Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nature Struct. Biol. 7 (2000) 560-564
19. Sandy J., Mushtaq A., Kawamura A., Sinclair J., Sim E., and Noble M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis-an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 318 (2002) 1071-1083
20. Rodrigues-Lima F., and Dupret J.M. 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem. Biophys. Res. Commun. 291 (2002) 116-123
21. Rodrigues-Lima F., Delomenie C., Goodfellow G.H., Grant D.M., and Dupret J.M. Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop. Biochem. J. 356 (2001) 327-334
22. Savulescu M.R., Mushtaq A., and Josephy P.D. Screening and characterizing human NAT2 variants. Methods Enzymol. 400 (2005) 192-215
23. Kawamura A., Graham J., Mushtaq A., Tsiftsoglou S.A., Vath G.M., Hanna P.E., et al. Eukaryotic arylamine N-acetyltransferase investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. 69 (2005) 347-359
24. Wang H., Vath G.M., Kawamura A., Bates C.A., Sim E., Hanna P.E., and Wagner C.R. Overexpression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 24 (2005) 65-75
25. Grant D.M., Blum M., Beer M., and Meyer U.A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 39 (1991) 184-191
26. Fretland A.J., Doll M.A., Gray K., Feng Y., and Hein D.W. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Toxicol. Appl. Pharmacol. 142 (1997) 360-366
27. Minchin R.F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J. 307 (1995) 1-3
28. Upton A., Smelt V., Mushtaq A., Aplin R., Johnson N., Mardon H., and Sim E. Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy. Biochim. Biophys. Acta 1524 (2000) 143-148
29. Kay L.E. Nuclear magnetic resonance methods for high molecular weight proteins: A study involving a complex of maltose binding protein and β-cyclodextrin. Methods Enzymol. 339 (2001) 174-190
30. Pervushin K.V., Wider G., Riek R., and Wuthrich K. The 3D NOESY-[(1)H,(15)N,(1)H]-ZQ-TROSY NMR experiment with diagonal peak suppression. Proc. Natl Acad. Sci. USA 96 (1999) 9607-9612
31. Matsuo H., Walters K., Teruya K., Tanaka T., Gassner G., Lippard S.J., et al. Identification by NMR spectroscopy of residues at contact surfaces in large, slowly exchanging macromolecular complexes. J. Am. Chem. Soc. 121 (1999) 9903-9904
32. Eddy S.R. Where did the BLOSUM62 alignment score matrix come from?. Nature Biotechnol. 22 (2004) 1035-1036
33. Henikoff S., and Henikoff J.G. Amino acid substitution matrices from protein blocks. Proc. Natl Acad. Sci. USA 89 (1992) 10915-10919
34. Overington J., Donnelly D., Johnson M.S., Sali A., and Blundell T.L. Environment-specific amino acid substitution tables: tertiary templates and prediction of protein folds. Protein Sci. 1 (1992) 216-226
35. Goodfellow G.H., Dupret J.M., and Grant D.M. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. 348 (2000) 159-166
36. Wüthrich K. NMR of Proteins and Nucleic Acids (1986), Wiley, New York
37. Walters K.J., Ferentz A.E., Hare B.J., Hidalgo P., Jasanoff A., Matsuo H., and Wagner G. Characterizing protein-protein complexes and oligomers by nuclear magnetic resonance spectroscopy. Methods Enzymol. 339 (2001) 238-258
38. Kang Y., Vossler R.A., Diaz-Martinez L.A., Winter N.S., Clarke D.J., and Walters K.J. UBL/UBA ubiquitin receptor proteins bind a common tetraubiquitin chain. J. Mol. Biol. 356 (2006) 1027-1035
39. Walters K.J., Lech P.J., Goh A.M., Wang Q., and Howley P.M. DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc. Natl Acad. Sci. USA 100 (2003) 12694-12699
40. Wang Q., Goh A.M., Howley P.M., and Walters K.J. Ubiquitin recognition by the DNA repair protein hHR23a. Biochemistry 42 (2003) 13529-13535
41. Dominguez C., Boelens R., and Bonvin M.J.J. HADDOCK: a protein-protein docking approach based on biochemical and/or biophysical information. J. Am. Chem. Soc. 125 (2003) 1731-1737
42. Sandy J., Holton S., Fullam E., Sim E., and Noble M. Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci. 14 (2005) 775-782
43. Hein D.W., Doll M.A., Rustan T.D., Gray K., Feng Y., Ferguson R.J., and Grant D.M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14 (1993) 1633-1638
44. Mushtaq A., Payton M., and Sim E. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem. 277 (2002) 12175-12181
45. Delgoda R., Lian L.Y., Sandy J., and Sim E. NMR investigation of the catalytic mechanism of arylamine N-acetyltransferase from Salmonella typhimurium. Biochim. Biophys. Acta 1620 (2003) 8-14
46. Martell K.J., Levy G.N., and Weber W.W. Cloned mouse N-acetyltransferases: enzymatic properties of expressed Nat-1 and Nat-2 gene products. Mol. Pharmacol. 42 (1992) 265-272
47. Hanna P.E. N-acetyltransferases, O-acetyltransferases, and N,O-acetyltransferases: enzymology and bioactivation. Advan. Pharmacol. 27 (1994) 401-430
48. Yu M.C., Skipper P.L., Taghizadeh K., Tannenbaum S.R., Chan K.K., Henderson B.E., and Ross R.K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J. Natl Cancer Inst. 86 (1994) 712-716
49. Sticha K.R., Sieg C.A., Bergstrom C.P., Hanna P.E., and Wagner C.R. Overexpression and large-scale purification of recombinant hamster polymorphic arylamine N-acetyltransferase as a dihydrofolate reductase fusion protein. Protein Expr. Purif. 10 (1997) 141-153
50. 13C, 2H-labeled proteins: application to a 37-kDa Trp repressor-DNA complex. J. Am. Chem. Soc. 116 (1994) 6464-6465
51. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., and Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6 (1995) 277-293
52. Bartels C., Xia T.-H., Billeter M., Güntert P., and Wüthrich K. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J. Biomol. NMR 6 (1995) 1-10
53. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography and NMR system: a new software system for macromolecular structure determination. Acta Crystallog. sect. D 54 (1998) 905-921
54. McDonald I.K., and Thornton J.M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238 (1994) 777-793